1. Search Result
Search Result
Results for "

LI/ARDS

" in MedChemExpress (MCE) Product Catalog:

48

Inhibitors & Agonists

1

Biochemical Assay Reagents

4

Peptides

2

Inhibitory Antibodies

4

Natural
Products

23

Recombinant Proteins

5

Antibodies

4

Click Chemistry

2

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-153530

    IPK Superfamily Neurological Disease Metabolic Disease
    LI-2242 is an inositol hexakisphosphate kinase (IP6K) inhibitor. LI-2242 has inhibition effect for IP6K1, IP6K2, IP6K3 and IPMK with IC50 values of 31 nM, 42 nM, 8.7 nM and 1944 nM, respectively. LI-2242 can be used for thew research of type II diabetes, obesity, metabolic complications, venous thrombosis, and psychiatric disorders .
    LI-2242
  • HY-N8207
    Gypenoside LI
    1 Publications Verification

    Apoptosis MicroRNA Cancer
    Gypenoside LI, a gypenoside monomer, possesses anti-tumor activity. Gypenoside LI induces cell apoptosis, cell cycle and migration .
    Gypenoside LI
  • HY-123905A

    Drug Isomer MicroRNA Parasite Infection Cancer
    LIN28 inhibitor LI71 enantiomer is the less active enantiomer of LIN28 inhibitor LI71 (HY-123905). LIN28 inhibitor LI71 is a LIN28 inhibitor that effectively inhibits LIN28:let-7 binding (IC50: 7 μM). LIN28 inhibitor LI71 can abolish LIN28-mediated oligouridylation of let-7 precursor (IC50: 27 μM). LIN28 inhibitor LI71 has potential application value in LIN28-driven cancer research. LIN28 inhibitor LI71 inhibits the interaction of cold shock protein of Plasmodium falciparum (PfCoSP) with DNA and α/β tubulin and has an inhibitory effect on Plasmodium falciparum .
    LIN28 inhibitor LI71 enantiomer
  • HY-136265

    Aminoacyl-tRNA Synthetase Cancer
    BC-LI-0186 is a potent and selective inhibitor of Leucyl-tRNA synthetase (LRS; LeuRS) and Ras-related GTP-binding protein D (RagD) interaction (IC50=46.11 nM). BC-LI-0186 competitively binds to the RagD interacting site of LRS (Kd=42.1 nM) and has on effects on LRS-Vps34, LRS-EPRS, RagB-RagD association, mTORC1 complex formation or the activities of 12 kinases. BC-LI-0186 can effectively suppress the activity of cancer-associated?MTOR?mutants and the growth of rapamycin-resistant cancer cells.?BC-LI-0186 is a promising agent for lung cancer research .
    BC-LI-0186
  • HY-123905

    MicroRNA Parasite Infection Cancer
    LIN28 inhibitor LI71 is a LIN28 inhibitor that effectively inhibits LIN28:let-7 binding (IC50: 7 μM). LIN28 inhibitor LI71 can abolish LIN28-mediated oligouridylation of let-7 precursor (IC50: 27 μM). LIN28 inhibitor LI71 has potential application value in LIN28-driven cancer research. LIN28 inhibitor LI71 inhibits the interaction of cold shock protein of Plasmodium falciparum (PfCoSP) with DNA and α/β tubulin and has an inhibitory effect on Plasmodium falciparum .
    LIN28 inhibitor LI71
  • HY-144256

    DNA/RNA Synthesis Cancer
    CHD1Li 6.11 is a potent oncogenic CHD1L inhibitor (IC50=3.3 µM for cat-CHD1L recombinant protein). CHD1Li 6.11 is an orally bioavailable antitumor agent, significantly reducing the tumor volume of CRC xenografts generated from isolated quasi mesenchymal cells (M-phenotype), which possess enhanced tumorigenic properties .
    CHD1Li 6.11
  • HY-150735

    IRAK Inflammation/Immunology
    IRAK4-IN-20 (Compound BAY-1834845) is an orally active IRAK4 inhibitor with an IC50 of 3.55 nM. IRAK4-IN-20 can be used for acute respiratory distress syndrome (ARDS) research .
    IRAK4-IN-20
  • HY-P4040

    HCV Protease Infection Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    Ac-D-DGla-LI-Cha-C is a potent HCV protease inhibitor peptide. Ac-D-DGla-LI-Cha-C can be used for the research of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases .
    Ac-D-DGla-LI-Cha-C
  • HY-RS04087

    Small Interfering RNA (siRNA) Others

    DYNC2LI1 Human Pre-designed siRNA Set A contains three designed siRNAs for DYNC2LI1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    DYNC2LI1 Human Pre-designed siRNA Set A
    DYNC2LI1 Human Pre-designed siRNA Set A
  • HY-RS04085

    Small Interfering RNA (siRNA) Others

    DYNC1LI1 Human Pre-designed siRNA Set A contains three designed siRNAs for DYNC1LI1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    DYNC1LI1 Human Pre-designed siRNA Set A
    DYNC1LI1 Human Pre-designed siRNA Set A
  • HY-150555

    Potassium Channel Others
    P-CAB agent 1 (compound B19) is a highly potent potassium-competitive acid blocker agent with an IC50 value of 60.50 nM for H +/K +-ATPase. P-CAB agent 1 has acceptable oral absorption in rats. P-CAB agent 1 can be used for researching acid-related disorders (ARDs) .
    P-CAB agent 1
  • HY-159131

    Histone Acetyltransferase Epigenetic Reader Domain Inflammation/Immunology
    PNSC928 is an inhibitor for the CtBP2-p300 interaction with an IC50 of 23.60 µM, and reverses the Lipopolysaccharides (HY-D1056)-induced expressions of proinflammatory cytokines in RAW264.7. PNSC928 ameliorates the acute respiratory distress syndrome (ARDS)in mice .
    PNSC928
  • HY-P99810

    AVTX-002; AEVI 002; SAR 252067; CERC-002; MDGN-002

    SARS-CoV Cardiovascular Disease
    Quisovalimab (AVTX-002; AEVI 002; SAR 252067) is a human monoclonal antibody against LIGHT, a tumor necrosis factor (TNF)-related cytokine (TNFSF14) that plays an important role in acute respiratory distress syndrome (ARDS) and cytokine release syndrome (CRS) COVID-19. Quisovalimab can be used in COVID-19 acute respiratory distress syndrome and other studies .
    Quisovalimab
  • HY-149862

    PROTACs Androgen Receptor Cancer
    ARD-2051 is a potent and orally active androgen receptor (AR) proteolysis-targeting chimera degrader. ARD-2051 achieves DC50 values of 0.6 nM for AR protein degradation in both the LNCaP and VCaP prostate cancer cell lines. ARD-2051 can be used for the research of prostate cancer .
    ARD-2051
  • HY-132292

    PROTACs Androgen Receptor Cancer
    ARD-2128 is a highly potent, orally bioavailable PROTAC androgen receptor (AR) degrader. ARD-2128 effectively reduces AR protein, suppresses AR-regulated genes in tumor tissues, and inhibits growth of tumor without signs of toxicity. ARD-2128 has the potential for the research of the prostate cancer .
    ARD-2128
  • HY-139659

    PROTACs Androgen Receptor Progesterone Receptor Apoptosis Cancer
    ARD-61 is a highly potent, effective and specific PROTAC androgen receptor (AR) degrader. ARD-61 potently and effectively induces AR and progesterone receptors (PR) degradation in AR+ cancer cell lines. ARD-61 induces apoptosis and effectively induces tumor growth inhibition in the MDA-MB-453 xenograft model in mice . ARD-61 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    ARD-61
  • HY-145390

    Keap1-Nrf2 Inflammation/Immunology
    Nrf2 activator-1 is a potent activator of NF-E2 related factor 2 (Nrf2). Nrf2 activator-1 has the potential for the research of COPD and other respiratory diseases, including asthma, Acute Lung Injury (ALI), Acute Respiratory Distress Syndrome (ARDS) and pulmonary fibrosis (extracted from patent WO2018109647A1) .
    Nrf2 activator-1
  • HY-156111

    PROTACs Androgen Receptor Cancer
    ARD-1676 is an orally available androgen receptor (AR) PROTAC degrader, consisting of AR ligand and cereblon ligand. ARD-1676 has AR-degrading activity in vitro and in vivo and inhibits VCaP tumor growth in mouse xenograft tumor models .
    ARD-1676
  • HY-145390A

    Keap1-Nrf2 Inflammation/Immunology
    (R,R)-Nrf2 activator-1 is the enantiomer of Nrf2 activator-1. Nrf2 activator-1 is a potent activator of NF-E2 related factor 2 (Nrf2). Nrf2 activator-1 has the potential for the research of COPD and other respiratory diseases, including asthma, Acute Lung Injury (ALI), Acute Respiratory Distress Syndrome (ARDS) and pulmonary fibrosis .
    (R,R)-Nrf2 activator-1
  • HY-139436

    PROTACs Androgen Receptor Cancer
    ARD-2585 is an exceptionally potent and orally active PROTAC degrader of androgen receptor .
    ARD-2585
  • HY-133020

    PROTACs Androgen Receptor Cancer
    ARD-266 is a highly potent and von Hippel-Lindau E3 ligase-based Androgen Receptor (AR) PROTAC degrader. ARD-266 effectively induces degradation of AR protein in AR-positive LNCaP, VCaP, and 22Rv1 prostate cancer cell lines with DC50 values of 0.2-1 nM . ARD-266 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    ARD-266
  • HY-133045

    Ligands for E3 Ligase Cancer
    VHL Ligand 8 is a VHL ligand. VHL Ligand 8 can be used to synthesize ARD-266 (HY-133020), a highly potent and VHL E3 ligase-based androgen receptor (AR) PROTAC degrader. ARD-266 effectively induces degradation of AR protein in AR-positive LNCaP, VCaP, and 22Rv1 prostate cancer cell lines with DC50 values of 0.2-1 nM .
    VHL Ligand 8
  • HY-W013249

    PROTAC Linkers Cancer
    Boc-piperazine-benzoic acid is a PROTAC linker and can be used in the synthesis of PROTACs, such as PROTAC androgen receptor (AR) degrader ARD-2128 (HY-13229) .
    Boc-piperazine-benzoic acid
  • HY-133046

    E3 Ligase Ligand-Linker Conjugates Cancer
    VHL Ligand-Linker Conjugates 17 incorporates a VHL ligand for the E3 ubiquitin ligase, and a PROTAC linker. VHL Ligand-Linker Conjugates 17 can be used in the synthesis of a series of PROTACs, such as ARD-266 (HY-133020). ARD-266 is a highly potent androgen receptor (AR) PROTAC degrader . VHL Ligand-Linker Conjugates 17 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    VHL Ligand-Linker Conjugates 17
  • HY-114402

    PROTACs Androgen Receptor Cancer
    ARD-69 is a PROTAC degrader based on the E3 ubiquitin ligase VHL and targeting the androgen receptor, which can induce androgen receptor (AR) protein degradation in AR-positive prostate cancer cells. ARD-69 inhibits AR-regulated gene expression, binds to the AR ligand binding domain at one end and binds to VHL at the other end, prompting AR to be recruited to the E3 ubiquitin ligase complex, triggering proteasome degradation, thereby inhibiting AR signaling pathways and downstream gene expression (such as PSA, TMPRSS2). ARD-69 can be used to study the treatment of castration-resistant prostate cancer (mCRPC) .
    ARD-69 is composed of a target protein ligand (pink part) AR antagonist 14 (HY-172624), a PROTAC linker (black part) tert-Butyl 4-ethynyl-[1,4'-bipiperidine]-1'-carboxylate (HY-W442074), and a VHL-type E3 ubiquitinase ligand (blue part) VH 101, acid (HY-47070); among them, the VHL ligand and the linker can form a conjugate VH 101-amide-piperidine-Pip-alkyne (HY-172625).
    ARD-69
  • HY-N6984

    Others Metabolic Disease
    Glycyroside is a isoflavone diglycoside isolated from Glycyrrhiza eurycarpa P. C. Li .
    Glycyroside
  • HY-130845

    Ligands for E3 Ligase Ligands for Target Protein for PROTAC Cancer
    AR antagonist 1 (compound 29) is a potent androgen receptor (AR) antagonist and binds to E3 ligase ligands with weak binding affinities to VHL protein in the synthesis of PROTAC ARD-266 (HY-133020).
    AR antagonist 1
  • HY-139660

    Ligands for Target Protein for PROTAC Cancer
    PROTAC PTK6 ligand-1 is an intermediate for BTK kinase inhibitor preparation . PROTAC PTK6 ligand-1 can be used in the synthesis of ARD-61 (HY-139659) .
    PROTAC PTK6 ligand-1
  • HY-130845A

    Ligands for E3 Ligase Ligands for Target Protein for PROTAC Androgen Receptor Cancer
    AR antagonist 1 (compound 29) hydrochloride is a potent androgen receptor (AR) antagonist and binds to E3 ligase ligands with weak binding affinities to VHL protein in the synthesis of PROTAC ARD-266 (HY-133020) .
    AR antagonist 1 hydrochloride
  • HY-133044

    PROTAC Linkers Cancer
    Boc-Pip-alkyne-Ph-COOH is a PROTAC linker, which refers to the alkyl/ether composition. Boc-Pip-alkyne-Ph-COOH can be used in the synthesis of a series of PROTACs, such as ARD-266 (HY-133020). ARD-266 effectively induces degradation of androgen receptor (AR) protein in AR-positive LNCaP, VCaP, and 22Rv1 prostate cancer cell lines with DC50 values of 0.2-1 nM . Boc-Pip-alkyne-Ph-COOH is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    Boc-Pip-alkyne-Ph-COOH
  • HY-162821

    IPK Superfamily Neurological Disease
    IP6K-IN-2 (compound 29c) is an orally bioavailable and blood-brain barrier permeable IP6K inhibitor (IC50: 15.8 nM) that can be used in the study of central nervous system diseases .
    LI-3948
  • HY-172624

    Ligands for Target Protein for PROTAC Cancer
    AR antagonist 14 is is a PROTAC target protein ligand (Ligands for Target Protein for PROTAC). AR antagonist 14 can be combined with VH 101-amide-piperidine-Pip-alkyne (HY-172625) to synthesize PROTAC degraders (ARD-69 (HY-114402)) .
    AR antagonist 14
  • HY-139661

    PROTAC Linkers Cancer
    Boc-bipiperidine-ethynylbenzoic acid is an Alkyl/ether-based PROTAC linker can be used in the synthesis of ARD-61 . Boc-bipiperidine-ethynylbenzoic acid is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    Boc-bipiperidine-ethynylbenzoic acid
  • HY-130846

    PROTAC Linkers Cancer
    Pip-alkyne-Ph-COOCH3 is an alkyl chain-based PROTAC linker can be used in the synthesis of PROTAC ARD-266 . Pip-alkyne-Ph-COOCH3 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    Pip-alkyne-Ph-COOCH3
  • HY-148162

    Biochemical Assay Reagents Others
    Kayexalate, a cation-exchange resin, is an orally active plasma potassium inhibitor. Kayexalate can be used in the research of hyperkalemia .
    Kayexalate
  • HY-N2317

    Bisdemethylcurcumin; LI-01008

    Endogenous Metabolite Neurological Disease
    Di-O-demethylcurcumin (Bisdemethylcurcumin) is an intestinal metabolite of curcumin with neuroprotective effects .
    Di-O-demethylcurcumin
  • HY-157914

    6,6-Dibenzyl-1,4,8,11-tetraoxacyclotetradecane

    Biochemical Assay Reagents Others
    Dibenzyl-14-crown-4 (6,6-Dibenzyl-1,4,8,11-tetraoxacyclotetradecane) is a crown ether derivate, which serves as neutral carrier in PVC ion-selective electrode, improves the Li + selectivity against Na + and K + .
    Dibenzyl-14-crown-4
  • HY-159159

    NOD-like Receptor (NLR) Inflammation/Immunology
    MS-II-124 is an effective and selective NLRP3 inhibitor (IC50=0.12 μM) with anti-inflammatory and immunomodulatory activities, which can be used in the research of acute lung injury (ALI)/acute respiratory distress syndrome (ARDS) .
    MS-II-124
  • HY-W008356

    Drug Intermediate Infection Metabolic Disease
    2-Fluoro-4-iodobenzonitrile is a building block, which can be used to synthesize L. infantum trypanothione reductase (Li-TryR) dimerization and oxidoreductase activity inhibitors. 2-Fluoro-4-iodo benzonitrile can also be used to synthesize transient receptor potential ankyrin 1 (TRPA1) antagonists .
    2-Fluoro-4-iodobenzonitrile
  • HY-126617

    NSC 258308

    Others Cancer
    Duclauxin decreases proliferation of tumor cells in vitro and increases the lifespan of mice innoculated with Ehrlich ascitic tumor cells. Duclauxin (10-30 μg/mL) inhibits mitochondrial respiration of P-388 tumor cells and nucleic acid synthesis in cell culture of Ehrlich cancer, the lymphadenomas NK/LI and L 5178, and sarcoma 37. Duclauxin also inhibits growth of wheat coleoptile.
    Duclauxin
  • HY-139374
    Zabedosertib
    1 Publications Verification

    BAY 1834845

    IRAK Inflammation/Immunology
    Zabedosertib (BAY 1834845) is a selective, orally active IRAK4 inhibitor with immunomodulatory potential, IC50 is 3.55 nM. IRAK4 is a protein kinase involved in signaling innate immune responses from Toll-like receptors . Zabedosertib exhibits anti-inflammatory property against IL-β, LPS (HY-D1056) and Imiquimod (HY-B1080) induced inflammation .
    Zabedosertib
  • HY-101817

    LI 32-468; S 32-468; Substance 32468

    Adrenergic Receptor Neurological Disease Endocrinology
    Spirendolol is a β adrenergic receptor antagonist.
    Spirendolol
  • HY-P10889

    Phosphatase Inflammation/Immunology
    CNI103 is a highly potent and metabolically stable cell-permeable peptide inhibitor of calcineurin. CNI103 selectively blocks the interaction between calcineurin and NFATc3 (KD=16 nM), thereby preventing NFATc3 activation in vitro and in vivo. CNI103 can be used to study acute respiratory distress syndrome (ARDS) and other inflammatory diseases .
    CNI103
  • HY-173485

    SARS-CoV COX Infection Inflammation/Immunology
    SARS-CoV-2 Mpro-IN-41 (Compound 7e) is an orally active inhibitor of COX-2 and SARS-CoV-2 M pro (IC50 values are 9.66 μM and 13.24 μM, respectively). SARS-CoV-2 Mpro-IN-41 also has a certain inhibitory activity against COX-1 (IC50: 46.11 μM). SARS-CoV-2 Mpro-IN-41 can significantly inhibit the expression of inflammatory-related cytokines (such as TNF-α, IL-6, IL-1β) and exert anti-inflammatory effects. SARS-CoV-2 Mpro-IN-41 exerts anti-inflammatory and antiviral effects by selectively inhibiting COX-2 and SARS-CoV-2 M pro. SARS-CoV-2 Mpro-IN-41 can be used for anti-inflammatory and anti-coronavirus research .
    SARS-CoV-2 Mpro-IN-41
  • HY-W012683

    Biochemical Assay Reagents Cancer
    Iminodiacetic acid is a metal ion chelator targeting Cr 6+, Cd 2+, Ni 2+, and Pb 2+. Iminodiacetic acid selectively and irreversibly binds metal ions through the coordination of carboxyl and imino groups, reduces the toxicity of metal ions and promotes their adsorption and separation. Iminodiacetic acid has the functions of heavy metal ion removal and coordination complex stabilization. Iminodiacetic acid is often used in environmental pollution control (such as heavy metal adsorption in water) and coordination chemistry (such as metal ion detection and separation) research .
    Iminodiacetic acid
  • HY-P991223

    Transmembrane Glycoprotein TNF Receptor Cancer
    NC762 is a humanized IgG1κ monoclonal antibody that targets human B7-H4 (B7 homolog 4). NC762 has enhanced binding to CD16a (FcγRIIIa) after being Fc engineered with three point mutations (S239D/A330L/I332E; DLE) and demonstrate increased antibody-dependent cellular cytotoxicity (ADCC) activity. NC762 inhibits tumor growth in vivo through binding to tumor-expressing B7-H4. NC762 can be studies in research on cancer such as advanced or metastatic solid tumors .
    NC762
  • HY-P0012A
    Aviptadil acetate
    1 Publications Verification

    Vasoactive Intestinal Peptide acetate salt (human, rat, mouse, rabbit, canine, porcine)

    SARS-CoV Infection Inflammation/Immunology
    Aviptadil acetate is an analog vasoactive intestinal polypeptide (VIP) with potent vasodilatory effects. Aviptadil acetate induces pulmonary vasodilation and inhibits vascular SMCs proliferation, platelet aggregation. Aviptadil acetate can be used for the research of pulmonary fibrosis, pulmonary arterial hypertension (PAH) and SARS-CoV-2 caused respiratory failure, et al .
    Aviptadil acetate
  • HY-P0012
    Aviptadil
    1 Publications Verification

    Vasoactive Intestinal Peptide (human, rat, mouse, rabbit, canine, porcine)

    SARS-CoV Infection Inflammation/Immunology
    Aviptadil is an analog vasoactive intestinal polypeptide (VIP) with potent vasodilatory effects. Aviptadil induces pulmonary vasodilation and inhibits vascular SMCs proliferation, platelet aggregation. Aviptadil can be used for the research of pulmonary fibrosis, pulmonary arterial hypertension (PAH) and SARS-CoV-2 caused respiratory failure, et al .
    Aviptadil

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: